Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments like cost synergies and reduced cash burn, revenue decline and reliance on major customers pose risks. The partnership with Illumina and growth in consumables are positives, but weak instrument sales and cautious guidance for China offset these gains. The Q&A highlights management's cautious stance and lack of specific guidance, which could concern investors. Given these mixed signals, the stock price is likely to remain neutral in the short term.
Key Financial Performance
Revenue $45 million (down 5% year-over-year); $128 million year-to-date (down 9% year-over-year). The decline is attributed to a challenging industry backdrop with tight customer budgets for CapEx equipment and conservative purchasing behaviors.
Consumables Revenue $14 million (up 13% year-over-year); $45 million year-to-date (up 21% year-over-year). Growth driven by expansion in SomaScan authorized sites and the Illumina Early Access program.
Instruments Revenue Just under $6 million (down 42% year-over-year); just under $20 million year-to-date (down 28% year-over-year). The decline is largely due to external capital spending constraints in the life sciences sector and extended weakness in China.
Lab Services Revenue $18 million (up over 1% year-over-year); $41 million year-to-date (down 23% year-over-year). The quarter benefited from favorable timing from large customer projects and new SomaScan customers.
Field Services Revenue Just over $6 million (down 4% year-over-year); $19 million year-to-date (flat compared to 2023). Revenue impacted by lower installation services on fewer instrument sales, offset by continued maintenance contracts.
Non-GAAP Gross Margin 57% in Q3 (up from 52% year-over-year); 53% year-to-date (up from 52% in 2023). Improvement driven by a shift in revenue mix towards higher consumables and improved quality yield.
Non-GAAP Operating Expenses $40 million in Q3 (down 24% year-over-year); $137 million year-to-date (down 22% year-over-year). Reduction attributed to ongoing realization of merger cost synergies and a one-time benefit from reduced annual bonus accrual.
Adjusted EBITDA $14 million loss in Q3 (50% improvement year-over-year); $69 million loss year-to-date (32% improvement year-over-year). The reduction reflects improved operational efficiency and cost management.
Cash Position $368 million as of September 30, 2024. Cash burn was $28 million in Q3 (58% reduction from Q2). Adjusted cash burn was about $21 million, representing a 23% reduction from Q2.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Announced the launch of single SOMAmer agent as a minimal viable product offering, making each of the 11,000 individuals SOMAmers available for purchase.
Consumables Growth: Consumables revenue was up 13% year-over-year in the quarter, driven by expansion in SomaScan authorized sites.
Market Expansion: Expanded footprint beyond core lab in Boulder to authorized SomaScan sites, including a major U.S. based bio farm customer.
SomaScan Partnership: Partnership remains on track for full commercial release in the first half of 2025, democratizing the SomaScan assay on Illumina’s installed base.
Operational Efficiency: Achieved a 24% year-over-year reduction in non-GAAP operating expenses year to date, and a 50% improvement in adjusted EBITDA in the quarter.
Delivery Performance: Achieved an industry-leading on-time delivery for products and services of 98%, up from 78% two years ago.
Strategic Focus: Targeting adjusted EBITDA break-even for the full year 2026, focusing on building a scaled and profitable life science company.
Consolidation Strategy: Actively assessing opportunities to accelerate consolidation in a fragmented and capital-constrained industry.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer Budget Constraints: The company is facing challenges due to tight customer budgets for capital expenditures (CapEx) equipment, leading to conservative purchasing behaviors.
Integration Risks: The ongoing integration with SomaLogic presents risks related to achieving expected synergies and operational efficiencies.
Market Competition: The company is operating in a highly competitive environment, particularly in the life sciences sector, which is affecting sales cycles and order delays.
Economic Factors: External economic conditions, including constraints in the life sciences sector and extended weakness in China, are elongating sales cycles and delaying orders.
Revenue Decline: Year-over-year revenue is down 5% for Q3 and 9% year-to-date, indicating potential challenges in maintaining growth.
Operating Expense Management: While there have been reductions in operating expenses, there are still lingering headwinds and one-time costs that the company must navigate.
Cash Burn: Despite a reduction in cash burn, the company reported a cash burn of $28 million in Q3, which could pose risks to liquidity.
Dependency on Major Customers: The lab services business has historically relied heavily on a few large customers, which poses risks if these customers reduce spending.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SomaLogic Integration: The team is three quarters into the SomaLogic integration and a full year ahead on cost reduction, having already operationalized expected $80 million in synergies.
Operational Efficiency: Achieved a 24% year-over-year reduction in non-GAAP operating expenses year to date and a 50% improvement in adjusted EBITDA in the quarter.
Consumables Focus: Consumables revenue was up 13% year-over-year, indicating a strategic focus on high-margin consumables as a growth area.
SomaScan Expansion: Expanding footprint beyond core lab locations and into authorized SomaScan sites, including partnerships with major U.S. biopharma customers.
Single SOMAmer Launch: Launched single SOMAmer agent as a minimal viable product, meeting an unmet need for protein identification and quantification.
Long-term Strategy: Targeting adjusted EBITDA break-even for the full year 2026, with a focus on scaling the business and diversifying end markets.
2024 Revenue Guidance: Reiterating full year 2024 revenue guidance in the range of $170 million to $175 million.
Cash Position: Ended Q3 with $368 million in cash and short-term investments, well-capitalized to advance strategic vision.
Adjusted Cash Burn: Total cash burn was $28 million in Q3, a 58% reduction from Q2, indicating improved cash management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Position: Standard BioTools ended the third quarter with approximately $368 million in cash, cash equivalents, restricted cash, and short-term investments.
Cost Synergies: The company has identified $80 million in target synergies from the merger with SomaLogic, expected to be fully realized in 2025.
Cash Burn: Total cash burn was $28 million in the third quarter, a 58% reduction from the previous quarter.
Adjusted Cash Burn: Excluding transaction, restructuring, and integration costs, the adjusted cash burn was about $21 million, representing a 23% reduction from the second quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you quantify what percent of assay services revenue in 3Q was timing based?
A:We had favorable timing in Q3, an unfavorable in Q2, with a hefty headwind on the order of $15 million to $20 million from our five large customers. Overall, we see double-digit growth in SomaScan asset services outside of those customers.
Q:Are you expecting any year-end budget flush or spending dynamics different from 3Q?
A:We don't expect a significant year-end budget flush, but we are building in a slight uptick on instruments for Q4.
Q:Can you talk about demand improvement and what's going on in China?
A:Instruments are down 28% year-to-date. We see cautious optimism in China, but we don't expect improvements to flow through in Q4. VC money is flowing into biotech, but it hasn't translated into revenue for us yet.
Q:Can you discuss the areas you're investing in and the launch of single Soma?
A:We are reducing cash burn while protecting growth investments. The single Soma launch is currently a minimal viable product, and we plan a broader launch once infrastructure is set up.
Q:Can you provide directional commentary for 2025?
A:Not at this time. We're focused on Q4 and will provide an updated view on 2025 later.
Q:Are there still delayed projects that will get recognized in Q4?
A:We had favorable timing this year and unfavorable last year. We have better visibility on large projects now.
Q:What are you seeing in markets outside of China?
A:We are doing well in the Americas and parts of Asia, but Europe has been challenging.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2025 and did not clarify the exact percentage of assay services revenue that was timing based.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO
Chief Officer
China
Field service
IMC
Illumina base
Instructions
Kim
PO sample
SBS culture
Slide
SomaScan site
Wyatt
application
backdrop
basis date
behavior
broadening
budget
capital
cash burn
digit
end market
focus
funnel
guide
industry
infrastructure
kind
lab service
loss
offering
order
project
protein
quality
script
side
th
vision
way
LAB Transcript
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Unknown5-6
The earnings call presents mixed signals: strong cost management and cash position are positive, but declining revenues, gross margins, and ongoing cash burn are concerning. The optimistic guidance and strategic partnerships offer potential upside, yet uncertainties in revenue timing and market conditions temper expectations. The Q&A session reveals cautious optimism but lacks clarity on key issues. Overall, the stock price is likely to remain neutral in the short term as positive strategic moves are counterbalanced by financial and operational challenges.
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings report highlights several negative factors: a 9% revenue decline, significant drops in instrument and lab services revenue, and decreased gross margins. Despite improved cost management and strong consumables growth, the overall financial performance is weak. The lack of a shareholder return plan and unclear management guidance further contribute to uncertainty. The Q&A session reveals limited confidence in market recovery and no specific guidance on cash burn. The positive Illumina partnership is overshadowed by broader financial challenges, leading to a likely negative stock reaction.
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed picture. While there are positive developments like cost synergies and reduced cash burn, revenue decline and reliance on major customers pose risks. The partnership with Illumina and growth in consumables are positives, but weak instrument sales and cautious guidance for China offset these gains. The Q&A highlights management's cautious stance and lack of specific guidance, which could concern investors. Given these mixed signals, the stock price is likely to remain neutral in the short term.
Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong partnership with Illumina, strategic capital allocation, and cost reductions are positive. However, declining revenues, gross margins, and CFO departure pose risks. The Q&A reveals management's limited transparency and reliance on a few large accounts, adding uncertainty. The share repurchase program offers some support, but overall, the mixed signals and lack of specific guidance adjustments suggest a neutral stock price movement in the short term.
LAB Slides
LAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
